Literature DB >> 22079609

The catalytic phosphoinositol 3-kinase isoform p110δ is required for glioma cell migration and invasion.

Sze Ki Luk1, Roland P Piekorz, Bernd Nürnberg, Shing-Shun Tony To.   

Abstract

Glioblastoma multiforme (GBM) is a highly invasive and aggressive primary brain tumour in which loss of phosphatase and tensin homologue deleted on chromosome 10 (PTEN), a negative regulator of PI3K signalling, is a common feature. PTEN/PI3K/Akt signalling is involved in the regulation of proliferation, apoptosis and cell migration. Deregulation of PI3K signalling is considered an essential driver in gliomagenesis. However, the role of different PI3K isoforms in glioma is still largely unclear. Here we show that the catalytic PI3K isoform p110δ is consistently expressed at a high level in various glioma cell lines. We used small interfering RNA to selectively deplete p110δ and to determine its tumourigenic roles in PTEN-deficient cells. Interestingly, knockdown of p110δ decreased the cell migration and invasion ability of all GBM cell lines tested. Mechanistically, p110δ knockdown reduced the protein levels of focal adhesion kinase and cell division cycle 42, key regulators of cellular migration. In contrast, pharmacologic inhibition of p110δ by IC87114 or CAL-101 also clearly impaired glioma cell migration but had no obvious effect on the invasion capacity thus pinpointing to possible kinase-dependent and -independent roles of p110δ in glioma pathology. In summary, our data provide novel evidence that in glioma cells p110δ is a key regulator of cell movement and thus may contribute to the highly invasive phenotype of GBM. Isoform specific targeting of PI3Kδ may be beneficial in the treatment of glioblastoma multiforme by specifically inhibiting tumour cell migration capacity.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22079609     DOI: 10.1016/j.ejca.2011.09.006

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  20 in total

1.  CXCL12-mediated murine neural progenitor cell movement requires PI3Kβ activation.

Authors:  Borja L Holgado; Laura Martínez-Muñoz; Juan Antonio Sánchez-Alcañiz; Pilar Lucas; Vicente Pérez-García; Gema Pérez; José Miguel Rodríguez-Frade; Marta Nieto; Oscar Marín; Yolanda R Carrasco; Ana C Carrera; Manuel Alvarez-Dolado; Mario Mellado
Journal:  Mol Neurobiol       Date:  2013-04-19       Impact factor: 5.590

2.  p87 and p101 subunits are distinct regulators determining class IB phosphoinositide 3-kinase (PI3K) specificity.

Authors:  Aliaksei Shymanets; Kirsten Bucher; Sandra Beer-Hammer; Christian Harteneck; Bernd Nürnberg
Journal:  J Biol Chem       Date:  2013-09-06       Impact factor: 5.157

Review 3.  Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding.

Authors:  Arshawn Sami; Michael Karsy
Journal:  Tumour Biol       Date:  2013-04-30

4.  Erlotinib resistance in EGFR-amplified glioblastoma cells is associated with upregulation of EGFRvIII and PI3Kp110δ.

Authors:  Alexander Schulte; Katrin Liffers; Annegret Kathagen; Sabine Riethdorf; Svenja Zapf; Adrian Merlo; Katharina Kolbe; Manfred Westphal; Katrin Lamszus
Journal:  Neuro Oncol       Date:  2013-07-21       Impact factor: 12.300

Review 5.  PI3K isoform-selective inhibitors: next-generation targeted cancer therapies.

Authors:  Xiang Wang; Jian Ding; Ling-hua Meng
Journal:  Acta Pharmacol Sin       Date:  2015-09-14       Impact factor: 6.150

Review 6.  Targeting the RAS oncogene.

Authors:  Asami Takashima; Douglas V Faller
Journal:  Expert Opin Ther Targets       Date:  2013-01-30       Impact factor: 6.902

Review 7.  Systematic review of protein biomarkers of invasive behavior in glioblastoma.

Authors:  Eli T Sayegh; Gurvinder Kaur; Orin Bloch; Andrew T Parsa
Journal:  Mol Neurobiol       Date:  2013-11-24       Impact factor: 5.590

8.  Different inhibition of Gβγ-stimulated class IB phosphoinositide 3-kinase (PI3K) variants by a monoclonal antibody. Specific function of p101 as a Gβγ-dependent regulator of PI3Kγ enzymatic activity.

Authors:  Aliaksei Shymanets; Oscar Vadas; Cornelia Czupalla; Jaclyn LoPiccolo; Michael Brenowitz; Alessandra Ghigo; Emilio Hirsch; Eberhard Krause; Reinhard Wetzker; Roger L Williams; Christian Harteneck; Bernd Nürnberg
Journal:  Biochem J       Date:  2015-07-01       Impact factor: 3.857

9.  Identifying molecular features associated with psychoneurological symptoms in women with breast cancer using multivariate mixed models.

Authors:  Qing Zhou; Colleen Jackson-Cook; Debra Lyon; Robert Perera; Kellie J Archer
Journal:  Cancer Inform       Date:  2015-05-07

Review 10.  Targeting RTK-PI3K-mTOR Axis in Gliomas: An Update.

Authors:  Mayra Colardo; Marco Segatto; Sabrina Di Bartolomeo
Journal:  Int J Mol Sci       Date:  2021-05-05       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.